Capricor Deramiocel Phase 3 Published in The Lancet; FDA Date Set for August 22
CAPR Capricor Therapeutics Inc
$4.17 -37.29%
차트·분석 보기 → - 1Capricor Therapeutics' (CAPR) Phase 3 HOPE-3 results for Duchenne muscular dystrophy treatment Deramiocel were published in The Lancet.
- 2In a trial of 106 patients, the drug reduced upper-limb function decline by 54% versus placebo, meeting the primary endpoint, and also reported cardiac function benefits.
- 3With the August 22 PDUFA date and advisory committee meeting approaching, the FDA had previously raised concerns over the original primary and secondary endpoints not being met and changes to the analysis plan.
This 3-line summary is compiled from the report below.
Stocktwits +1 View original ↗🎯 오늘의 AI 픽 5종목, 무료로 전부 공개합니다
숨기는 것 없이 — 지난 픽의 성적표(S&P500 대비)까지 그대로 보여드립니다